The partnership will focus on oncology research and accelerate the development of potential novel therapeutics for patients in need.

As a global leader in cancer treatment, Sheba possesses unique know-how that we are committed to sharing in order to improve healthcare across the globe, recognizing that collaboration is key to advancing care.

In that light, we are proud to announce a new partnership with Regeneron, a leading global biotechnology company. Together, Sheba and Regeneron will foster oncology research aimed at delivering new therapies for patients worldwide.

“We are excited and proud to partner with Regeneron to accelerate clinical research and to enhance patient access to novel treatments,” says Prof. Yitshak Kreiss, Director General of Sheba Medical Center. “This latest agreement exemplifies our mutual desire to improve patient outcomes with an emphasis on creating a better quality of life.”

Founded and led for nearly 35 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates.

“The Regeneron team is pleased to collaborate with Sheba to accelerate clinical studies of novel oncology therapeutics for patients in need,” stated Dr. David Weinreich, Executive Vice President, Global Clinical Development of Regeneron. “As we work to turn innovative science into vital medicines, we will partner with centers of excellence like Sheba that have established best practice clinical trial processes. We will also share knowledge through programs such as our joint Post-Doctoral Research program because we know that fighting cancer requires cooperation from the best minds worldwide.”

Regeneron to Partner with Sheba’s Precission Medicine Hub

As part of the collaboration between Sheba and Regeneron, the latter will partner with the Precision Medicine Hub of Sheba’s ARC (Accelerate, Redesign and Collaborate) Innovation Center, which is dedicated to developing cutting-edge, tailored treatments for individual patients through the use of genomic, proteomic, microbiome, and other data. With that purpose in mind, Regeneron is also set to join Sheba’s HealthTech Valley, a growing global ecosystem focused on redesigning healthcare by bringing together academia, industry, and medicine.

More Posts

Sheba Medical Center Join General Catalyst’s Health Assurance Ecosystem to Advance Innovative Medical Solutions

Sheba Medical Center Join General Catalyst’s Health Assurance Ecosystem to Advance Innovative Medical Solutions

General Catalyst is a leading US-based venture capital firm specializing in early-stage and growth investments across various industries, including technology, healthcare, and consumer goods. Known for its strategic approach and deep industry knowledge, General Catalyst not only provides financial support to entrepreneurs but also offers valuable guidance and resources to help them navigate the complex challenges of building and expanding their businesses.

read more